Obata, Atsushi
Kimura, Tomohiko
Obata, Yoshiyuki
Shimoda, Masashi
Kinoshita, Tomoe
Kohara, Kenji
Okauchi, Seizo
Hirukawa, Hidenori
Kamei, Shinji
Nakanishi, Shuhei
Mune, Tomoatsu
Kaku, Kohei
Kaneto, Hideaki
Funding for this research was provided by:
Research Project Grants from the Kawasaki Medical School (28-101)
a Grant-in-Aid from the Japan Society for the Promotion of Science (17K16157)
The Japan Foundation for Applied Enzymology
Article History
Received: 17 January 2019
Accepted: 15 March 2019
First Online: 4 May 2019
Change Date: 11 October 2019
Change Type: Correction
Change Date: 11 October 2019
Change Type: Correction
Change Details: It has been brought to our attention that Fig. 5a showing the vasculature in islets of controlfloxmice is not in fact an endocrine cell but rather exocrine tissue.
Change Details: It has been brought to our attention that Fig. 5a showing the vasculature in islets of controlfloxmice is not in fact an endocrine cell but rather exocrine tissue.
Duality of interest
: K.Ka has been an advisor to, received honoraria for lectures from and received scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Takeda, Taisho Pharmaceutical Co., Ltd, MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Nippon Boehringer Ingelheim Co., Ltd, Chugai, Daiichi Sankyo and Sanofi. HK has received honoraria for lectures and received scholarship grants from Sanofi, Novo Nordisk, Lilly, Boehringer Ingelheim, MSD, Takeda, Ono Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Pfizer, Kissei Pharma, AstraZeneca, Astellas, Novartis, Kowa, Chugai and Taisho Pharma. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.